BridgeBio Pharma, Inc. (BBIO) Earnings Call Analysis

NASDAQ · Unknown · Unknown

17/25

Growth 5 Margin 3 Expansion 3 Platform 3 Financial 3

latest quarter score

Earnings Reports

17
BridgeBio Pharma (BBIO) Q2 2026: Attruby U.S. Revenue Surges $150M as Pipeline Advances to FDA Review
August 11, 2026
18
BridgeBio Pharma (BBIO) Q1 2026: Atruvi Sales Surge 392%, Buyback Launch Signals Undervalued Pipeline
May 08, 2026
15
BridgeBio (BBIO) Q4 2025: Atruby Prescriber Base Jumps to 1,856, Signaling Deepening Franchise Penetration
February 25, 2026
13
BridgeBio (BBIO) Q3 2025: Dual Phase 3 Wins Drive 70%+ Technical Success, Expanding Rare Disease Pipeline
October 30, 2025
15
BridgeBio (BBIO) Q2 2025: Atruby Scripts Surge 30% as Pipeline Readouts Near
August 06, 2025
14
BridgeBio (BBIO) Q1 2025: Atruby Launch Delivers $36.7M, Accelerating Genetic Medicine Platform
July 06, 2025

Browse all companies